Open AccessNecessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
Author(s) -
Ako Gannichida,
Yusuke Nakazawa,
Akira Kageyama,
Hirofumi Utsumi,
Kazuyoshi Kuwano,
Takashi Kawakubo
Publication year - 2022
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v13.i7.641
Subject(s) - medicine , nivolumab , neutrophil to lymphocyte ratio , incidence (geometry) , immune system , lymphocyte , adverse effect , cancer , retrospective cohort study , gastroenterology , immunotherapy , immunology , physics , optics
Low neutrophil-to-lymphocyte ratio (NLR) has been shown to be associated with a favorable therapeutic response to nivolumab. The activation of immunocompetent cells such as lymphocytes exhibits an antitumor effect; however, the development of excessive immune responses in autologous organs along with the breakdown of self-tolerance causes immune-related adverse events, including hypothyroidism. Therefore, the possibility that NLR is associated with immune response shows that NLR can be not only a predictive factor for good response to nivolumab but also a predictive factor for the development of hypothyroidism.